Holen Sie sich die Stockscreener-App
8.825
10.04%
0.805
Schlusskurs vom Vortag:
$8.02
Offen:
$8.24
24-Stunden-Volumen:
825.18K
Relative Volume:
0.63
Marktkapitalisierung:
$625.77M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-43.51M
KGV:
-6.5785
EPS:
-1.3415
Netto-Cashflow:
$-39.73M
1W Leistung:
-1.18%
1M Leistung:
-15.63%
6M Leistung:
+42.57%
1J Leistung:
+16.89%
1-Tages-Spanne:
$8.15
$8.8299
1-Wochen-Bereich:
$7.51
$8.74
52-Wochen-Spanne:
$4.50
$11.45
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
8.825 | 625.77M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
505.00 | 128.00B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
228.41 | 91.19B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
788.25 | 81.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
827.38 | 52.03B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.50 | 42.02B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Sell |
| 2026-09-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2026-09-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-03 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet reports 57% IGA success at Week 52 - grafa.com
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance Singapore
Inflammatory acne lesions fell 77% over 52 weeks - Stock Titan
Warrants carry a 9.99% ownership cap in a passive Sagimet Biosciences (SGMT) stake. - Stock Titan
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance UK
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewswire
Sagimet raised about $115 million, with an acne drug trial among its planned uses. - Stock Titan
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Yahoo Finance UK
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Yahoo Finance
Sagimet Biosciences (Nasdaq:SGMT)Stock Analysis - Simply Wall Street
Sagimet prices $115 million stock offering at $10 per share By Investing.com - Investing.com Nigeria
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data - Yahoo Finance
Stock sales through Leerink are suspended at Sagimet Biosciences (SGMT). - Stock Titan
Sagimet Reports 52-Week Denifanstat Acne Trial Results - grafa.com
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell - Yahoo Finance
Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants - TradingView
Sagimet Biosciences Announces Pricing of $115.0 Million - globenewswire.com
About $115 million from a share sale is expected to help fund Sagimet's acne trial and other drug work. - Stock Titan
A 240-patient open-label acne extension yields 52-week results for Sagimet (SGMT). - Stock Titan
Sagimet Biosciences Raises $115 Million in Stock Offering - Intellectia AI
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - GlobeNewswire Inc.
A 52-week acne trial in China showed further improvement across all secondary measures. - Stock Titan
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Nigeria
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com Canada
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com India
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8 - marketscreener.com
Barclays upgrades Sagimet stock rating on acne drug potential - investing.com
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com India
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Canada
Barclays upgrades Sagimet stock rating on acne drug potential - Investing.com
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - Yahoo Finance
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of - GlobeNewswire
Sagimet (SGMT) Earnings Report: Profit Per Share Clears Its Benchmark in Latest Trading - vinanet.vn
Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Sagimet Biosciences Inc.Series A Common Stock (SGMT) Stock Price, News, Quote & History - FinancialContent
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - Yahoo Finance
Three New Hires Get Stock Options That Vest Over Four Years at Sagimet - Stock Titan
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kemble George | Director |
Aug 14 '26 |
Sale |
10.23 |
350,987 |
3,591,580 |
62,161 |
| GEORGE KEMBLE | Director |
Aug 14 '26 |
Proposed Sale |
9.28 |
350,987 |
3,257,159 |
0 |
| Kemble George | Director |
Aug 11 '26 |
Option Exercise |
6.36 |
20,206 |
128,510 |
82,367 |
| Kemble George | Director |
Aug 11 '26 |
Sale |
9.95 |
20,206 |
201,147 |
62,161 |
| GEORGE KEMBLE | Director |
Aug 11 '26 |
Proposed Sale |
9.57 |
20,206 |
193,371 |
0 |
| Happel David | President & CEO |
Jul 20 '26 |
Sale |
7.76 |
64,051 |
497,068 |
741,570 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Jul 20 '26 |
Sale |
7.76 |
10,545 |
81,832 |
224,414 |
| Kemble George | Director |
Jul 20 '26 |
Sale |
7.46 |
18,844 |
140,529 |
62,161 |
| GEORGE KEMBLE | Director |
Jul 20 '26 |
Proposed Sale |
7.82 |
18,844 |
147,360 |
0 |
| Happel David | President & CEO |
Feb 10 '26 |
Sale |
5.36 |
12,101 |
64,865 |
677,621 |
0.61%
6.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):